Study: Omicron evades some but not all monoclonal antibodies

Several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the omicron variant now sweeping across the United States, researchers reported Jan. 19 in the journal Nature Medicine.

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic - ScienceDirect

Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies - eBioMedicine

Omicron Is WHO's Fifth Variant of Concern, Experts Urge Patience

COVID-19 – Omicron: resistant to most monoclo

SARS-CoV-2 Study Forecasts Emergence of Immune Escape Variants

Emerging evidence on Omicron (B.1.1.529) SARS‐CoV‐2 variant - Sharma - 2022 - Journal of Medical Virology - Wiley Online Library

Monoclonal antibodies lock down SARS-CoV-2 spike: Trends in Immunology

Archive, monoclonal antibodies

Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys

Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers

The Omicron Variant Partly Dodged Vaccines In A Blood Study

SARS‑CoV‑2 Omicron variant escapes monoclonal antibodies

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages - ScienceDirect

Antibodies, Free Full-Text